Barclays PLC Buys 126,503 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Barclays PLC increased its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 182.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 195,793 shares of the medical instruments supplier’s stock after buying an additional 126,503 shares during the quarter. Barclays PLC owned 0.26% of OraSure Technologies worth $836,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Millennium Management LLC grew its stake in shares of OraSure Technologies by 727.5% in the 2nd quarter. Millennium Management LLC now owns 2,021,126 shares of the medical instruments supplier’s stock worth $8,610,000 after acquiring an additional 1,776,867 shares in the last quarter. American Century Companies Inc. grew its position in OraSure Technologies by 30.1% in the 2nd quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier’s stock worth $7,710,000 after purchasing an additional 418,603 shares in the last quarter. Renaissance Technologies LLC increased its stake in OraSure Technologies by 20.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier’s stock valued at $9,749,000 after buying an additional 391,100 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in OraSure Technologies in the 2nd quarter valued at about $1,602,000. Finally, Squarepoint Ops LLC lifted its position in shares of OraSure Technologies by 1,348.5% during the 2nd quarter. Squarepoint Ops LLC now owns 249,641 shares of the medical instruments supplier’s stock worth $1,063,000 after buying an additional 232,407 shares in the last quarter. 93.50% of the stock is owned by hedge funds and other institutional investors.

OraSure Technologies Stock Performance

Shares of NASDAQ:OSUR opened at $3.76 on Thursday. The company has a market capitalization of $280.47 million, a P/E ratio of 25.07 and a beta of 0.05. The company’s 50-day moving average is $3.83 and its 200 day moving average is $4.10. OraSure Technologies, Inc. has a fifty-two week low of $3.52 and a fifty-two week high of $8.33.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The firm had revenue of $39.92 million for the quarter, compared to analysts’ expectations of $38.97 million. During the same period in the previous year, the company earned $0.27 earnings per share. The company’s quarterly revenue was down 55.2% on a year-over-year basis. As a group, research analysts predict that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, January 9th.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.